Editorial & Columns Pay Gap in Indian Pharmaceutical Industry: Remuneration of Managerial Personnel vis-à-vis Employees October 23, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Board Characteristics of Pharmaceutical Companies in India August 28, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Reporting on Scope 3 Emissions: Learning from Global Pharmaceutical MNCs August 21, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Divestitures in Pharmaceutical Industry: Indian Experience July 25, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Evaluation and Revival of Special Economic Zones in India July 18, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Spin-off by Pharmaceutical Companies in India: Improved Focus and Valuation July 11, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Valuation Premium: India-listed Subsidiaries of Pharma and Healthcare MNCs Outshine Parent firms June 26, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns ESG Frameworks and Pharmaceutical Industry in India June 6, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Pharma 2.0: Indian Pharmaceutical Companies strive to Create & Enhance Strength in Biopharmaceuticals May 2, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Patent Expiry & Innovator Pharmaceutical Companies : Mechanisms applied to preserve market dominance April 24, 2024 | Dr. Anil Kumar Angrish | No Comments | More